Healthcare Sales & Marketing Network News: angioedema

Searching News Database: angioedema

HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 31 Jul 2023
Viatris Announces Launch of Breyna(TM) (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort(R) for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 13 May 2022
Medtronic completes acquisition of Intersect ENT
Devices Mergers & Acquisitions

HSMN NewsFeed - 14 Dec 2021
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals

HSMN NewsFeed - 20 Jul 2021
Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST(R) in the Middle East and North Africa
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals

HSMN NewsFeed - 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Feb 2021
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
Biopharmaceuticals

HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 3 Jul 2020
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA

HSMN NewsFeed - 26 May 2020
Emgality(R) Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
Biopharmaceuticals Neurology

HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 7 Feb 2020
Pharvaris Appoints Peng Lu, M.D., Ph.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Dec 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality(R) (galcanezumab-gnlm)
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Dec 2019
European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Dec 2019
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement

HSMN NewsFeed - 18 Oct 2019
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 10 Sep 2019
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Aug 2019
Lilly Announces Positive Results for Emgality(R) (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Jul 2019
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality(R) (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Jul 2019
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality(R) (galcanezumab-gnlm) in Episodic Cluster Headache
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz(R) (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Apr 2019
CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA(R) [Alpha1-Proteinase Inhibitor (Human)]
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2018
Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena(R) (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals

HSMN NewsFeed - 23 Aug 2018
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
Biopharmaceuticals Product Launch

HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals

HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 16 Mar 2018
FDA Approves Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals

HSMN NewsFeed - 17 Jan 2018
Pharming Announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
Biopharmaceuticals Endocrinology Product Launch

HSMN NewsFeed - 12 Dec 2017
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Nov 2017
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Nov 2017
Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 13 Nov 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 10 Nov 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate(R) (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals

HSMN NewsFeed - 15 Sep 2017
New indication for BRIVIACT(R) (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Aug 2017
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Aug 2017
Impax Announces Settlement of Contract Litigation on Opana(R) ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets
Biopharmaceuticals Litigation

HSMN NewsFeed - 25 Jul 2017
HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Biopharmaceuticals Product Launch

HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals

HSMN NewsFeed - 1 May 2017
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
Biopharmaceuticals Ophthalmology Licensing

HSMN NewsFeed - 3 Apr 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Mar 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients
Biopharmaceuticals

HSMN NewsFeed - 16 Mar 2017
Shire Receives European Approval for Label Extension of CINRYZE(R) (C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Jan 2017
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Dec 2016
Aralez Announces Commercial Launch Of BLEXTEN(TM) In Canada
Biopharmaceuticals Product Launch

HSMN NewsFeed - 8 Dec 2016
Pharming Announces Completion of Acquisition of All North American Commercialisation Rights for RUCONEST(R) From Valeant
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 29 Nov 2016
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Nov 2016
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Oct 2016
Shire Granted EU Marketing Authorization of Onivyde(R), in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Oct 2016
Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Sep 2016
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Aug 2016
Arrowhead Pharmaceuticals Closes $45 Million Private Offering
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 1 Aug 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Jul 2016
Shire Receives Extension of Market Authorization in Europe for Revestive(R) (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Jun 2016
Keryx Biopharmaceuticals Appoints Two New Board Members
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Apr 2016
Aralez Receives Health Canada Approval For BLEXTEN(TM)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Apr 2016
Impax Announces Availability of EMVERM(TM) (mebendazole) Chewable Tablets, 100 mg
Biopharmaceuticals Product Launch

HSMN NewsFeed - 7 Apr 2016
Pharming Announces Adoption by the European Commission of the CHMP Recommendation to Change the Terms of the Marketing Authorisation for Ruconest(R)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 4 Apr 2016
Therabron Therapeutics Appoints Eric Richman as an Independent Board Member
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch

HSMN NewsFeed - 17 Feb 2016
Impax Receives FDA Approval for Generic Version of Adderall XR(R) (mixed salts of a single-entity amphetamine product) Capsules, CII
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 8 Feb 2016
Global Blood Therapeutics Announces Changes to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jan 2016
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients 6 Years and Older
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 15 Jan 2016
Impax Receives Approval of EMVERM(TM) (mebendazole) Chewable Tablets, 100 mg
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Nov 2015
Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Oct 2015
Teva Announces Exclusive Launch of Generic Avodart(R) Capsules in the United States
Biopharmaceuticals Urology Generics Product Launch

HSMN NewsFeed - 28 Jul 2015
U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Jul 2015
KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 2 Feb 2015
FDA Approves New Dosing Option for CSL Behring's Hizentra(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Nov 2014
Salix and Pharming Announce the Launch of RUCONEST(R) in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals Product Launch

HSMN NewsFeed - 1 Aug 2014
FDA Approves Boehringer Ingelheim's Striverdi(R) Respimat(R) (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Jul 2014
Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA

HSMN NewsFeed - 5 Feb 2014
aTyr Pharma Appoints Frederic Chereau as President and Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Dec 2013
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 22 Nov 2013
Tivicay(R) (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 11 Nov 2013
Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Nov 2013
Salix Pharmaceuticals to Acquire Santarus
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Oct 2013
FDA Files Genentech’s Supplemental Biologics License Application of Xolair(R) (omalizumab) for Chronic Idiopathic Urticaria (CIU)
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Jul 2013
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor)
Biopharmaceuticals Devices Interventional Cardiology

HSMN NewsFeed - 23 Jul 2013
Fred Cohen Appointed to BioCryst’s Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jun 2013
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 29 Apr 2013
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 28 Feb 2013
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
Biopharmaceuticals Surgery FDA

HSMN NewsFeed - 21 Feb 2013
Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset Seizures
Biopharmaceuticals Neurology

HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 31 Jan 2013
Dyax Corp. and Novellus Biopharma AG Announce Partnership to Develop and Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in Latin America
Biopharmaceuticals Licensing

HSMN NewsFeed - 30 Nov 2012
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Oct 2012
BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Oct 2012
Study Supports Efficacy, Safety of Hizentra(R) in Japanese Patients with Primary Immunodeficiency Disease
Biopharmaceuticals

HSMN NewsFeed - 20 Aug 2012
Dyax Corp. Creates COO Position and Expands Executive Roles
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals

HSMN NewsFeed - 21 Jun 2012
FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review
Biopharmaceuticals FDA

HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 May 2012
Pfizer Reports Top-Line Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy
Biopharmaceuticals

HSMN NewsFeed - 4 May 2012
Pfizer Stops Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Neuropathic Pain Associated With HIV Neuropathy
Biopharmaceuticals

HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Apr 2012
Transcept Pharmaceuticals Announces National Product Launch of Intermezzo(R) by Purdue Pharma L.P.
Biopharmaceuticals

HSMN NewsFeed - 15 Mar 2012
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
Biopharmaceuticals Surgery

HSMN NewsFeed - 15 Feb 2012
Santarus Announces FDA Acceptance of UCERIS New Drug Application for Induction of Remission of Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 13 Feb 2012
Santarus Announces Initiation of Phase IIIb Study with UCERIS in Patients with Mild or Moderate Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 6 Feb 2012
Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE
Biopharmaceuticals

HSMN NewsFeed - 3 Jan 2012
CSL Behring Receives FDA Approval of Expanded Label on Berinert(R) for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 16 Dec 2011
Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (prebabalin) Capsules CV In Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 28 Nov 2011
CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Oct 2011
FDA Approves Combivent(R) Respimat(R) (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Sep 2011
NPS Pharmaceuticals Appoints Eric Pauwels as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Sep 2011
ViroPharma's Buccolam(R) (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 26 Aug 2011
NUCYNTA(R) ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Jun 2011
Pfizer’s Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord Injury
Biopharmaceuticals

HSMN NewsFeed - 5 Apr 2011
Merck to Acquire Inspire Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals

HSMN NewsFeed - 22 Mar 2011
Data Presented at AAAAI Annual Meeting Further Support the Safety and Efficacy of FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 28 Feb 2011
Shire Files Complete Response to FDA's Not Approvable Letter for FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Feb 2011
Santarus and Pharming Announce Receipt of FDA Refusal to File Letter for RHUCIN Biologics License Application
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Feb 2011
Santarus and Pharming Announce Initiation of Phase IIIb Clinical Study with RHUCIN in Acute Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 27 Jan 2011
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Jan 2011
Dyax and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema
Biopharmaceuticals Licensing

HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Biopharmaceuticals

HSMN NewsFeed - 28 Dec 2010
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
Biopharmaceuticals

HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology

HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
Biopharmaceuticals

HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Biopharmaceuticals

HSMN NewsFeed - 10 Sep 2010
FDA Approves New Dosing for FASLODEX(R) (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Aug 2010
Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Aug 2010
Data from First Phase 3 Trial (EDEMA3(R)) for KALBITOR(R) (ecallantide) Published in The New England Journal of Medicine
Biopharmaceuticals

HSMN NewsFeed - 25 May 2010
Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Apr 2010
Novartis Receives US FDA Approval for Zortress(R) (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jan 2010
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 28 Jan 2010
Teva UK Limited Launches Dorzolamide 2% Eye Drops Solution
Biopharmaceuticals Generics Ophthalmology

HSMN NewsFeed - 13 Jan 2010
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Jan 2010
ViroPharma Expands Global Licensing, Commercialization and Development Rights for Cinryze(TM) (C1 esterase inhibitor [human])
Biopharmaceuticals Licensing

HSMN NewsFeed - 7 Dec 2009
FDA Grants First Approval for a Product Derived from Pichia pastoris
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Dec 2009
Dyax Announces FDA Approval of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Nov 2009
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 12 Oct 2009
CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Jul 2009
Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
Biopharmaceuticals Urology Oncology FDA

HSMN NewsFeed - 12 Jun 2009
BARI 2D Study Presented at American Diabetes Association Scientific Sessions Underscores Utility of SPECT Myocardial Perfusion Imaging in Identifying Cardiovascular Risk and Evaluating Treatment Outcomes for Patients with Type 2 Diabetes
Biopharmaceuticals Radiology Cardiology

HSMN NewsFeed - 8 Jun 2009
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Apr 2009
Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Apr 2009
Prodarsan(R) granted Orphan Drug designation from FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Apr 2009
Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
Biopharmaceuticals

HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Feb 2009
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
Biopharmaceuticals

HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 9 Feb 2009
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Biopharmaceuticals

HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Feb 2009
FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 24 Nov 2008
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals

HSMN NewsFeed - 21 Oct 2008
ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 7 Aug 2008
Dyax Corp. Announces the Appointment of George Migausky as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Jul 2008
ViroPharma To Acquire Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 15 Jul 2008
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jul 2008
Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 10 Jun 2008
Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Biopharmaceuticals

HSMN NewsFeed - 21 May 2008
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Biopharmaceuticals Urology

HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 6 May 2008
Lev Pharmaceuticals Announces Cinryze(TM) Complete Response Submission Accepted for Review by FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 2 May 2008
Lev Announces FDA Advisory Committee Unanimously Recommends Approval of Cinryze(TM) for Hereditary Angioedema
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Apr 2008
FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA
Biopharmaceuticals Devices Drug Delivery Oncology FDA

HSMN NewsFeed - 24 Apr 2008
Two Merck Medicines Recommended for Approval in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Apr 2008
Jerini Receives Positive CHMP Opinion Recommending European Approval for Icatibant in the Treatment of HAE; FDA Issues Not Approvable Letter
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Apr 2008
Jerini AG -- FDA Issues Not Approvable Letter for Icatibant in the Treatment of HAE
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Apr 2008
Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications
Biopharmaceuticals

HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2008
Lev Pharmaceuticals Announces Submission of Complete Response to FDA for Cinryze(TM) for Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 27 Mar 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Mar 2008
Pharming signs distribution agreement for Rhucin(R) in Turkey
Biopharmaceuticals Distribution

HSMN NewsFeed - 20 Mar 2008
Pharming to receive Negative Opinion on European Marketing Authorization Application for Rhucin(R)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 Mar 2008
CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 11 Feb 2008
ACAAI Publishes New Supplement on Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Nov 2007
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 15 Nov 2007
Dyax Announces Plans for Retirement of Steve Galliker as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Nov 2007
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 31 Oct 2007
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Oct 2007
Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Oct 2007
FDA Approves Supplemental New Drug Applications for JANUVIA(TM) (sitagliptin)
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 24 Sep 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Sep 2007
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 10 Sep 2007
Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 4 Sep 2007
Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America
Biopharmaceuticals

HSMN NewsFeed - 30 Aug 2007
Pharming Presents Positive Results from European Phase III Trial of Rhucin(R)
Biopharmaceuticals

HSMN NewsFeed - 31 Jul 2007
Lev Pharmaceuticals Submits Biologics License Application for Cinryze(TM)
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jun 2007
Lev Pharmaceuticals, Inc. Announces Completion of Marketing and Sales Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Jun 2007
PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Jun 2007
Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 21 May 2007
Single-Tablet Combination of Tekturna(R) and Diuretic, an Important New Option for People With High Blood Pressure, Accepted for Review in U.S.
Biopharmaceuticals Cardiology

HSMN NewsFeed - 14 May 2007
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
Biopharmaceuticals Surgery Cardiology

HSMN NewsFeed - 4 May 2007
Dyax Announces the Resignation of Thomas Beck, M.D., President and Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 30 Apr 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Apr 2007
Dyax Announces the Appointment of Gustav Christensen as Executive Vice President and Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Apr 2007
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
Biopharmacetuicals

HSMN NewsFeed - 12 Apr 2007
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
Biopharmaceuticals

HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 5 Apr 2007
PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 29 Mar 2007
Pharming Strengthens Organization for Commercial Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Mar 2007
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 6 Mar 2007
Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 27 Feb 2007
Study Finds C1-Inhibitor Concentrate Is Safe and Effective in Treating Skin Swelling in Patients With Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 16 Jan 2007
Pharming Receives European Orphan Drug Designation
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Jan 2007
Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease
Biopharmaceuticals

HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Nov 2006
Positive Final Results from EDEMA2 Trial with DX-88 for the Treatment of Hereditary Angioedema Presented at ACAAI Meeting
Biopharmaceuticals

HSMN NewsFeed - 1 Nov 2006
Pharming Shareholders Appoint Bruno Giannetti as Member of the Board of Management
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals

HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Sep 2006
Kos Announces Positive Overall Results for Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema
Biopharmaceuticals

HSMN NewsFeed - 12 Sep 2006
Pharming Appoints Bruno Giannetti as Chief Operations Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jul 2006
Pharming Submits Marketing Authorisation Application for Recombinant Human C1 Inhibitor in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Jun 2006
Halozyme and Baxter Announce Availability of Hylenex for Subcutaneous Delivery of Medications and Fluids
Biopharmaceuticals

HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals

HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 24 May 2006
Dyax Announces the Appointment of Peggy Berry as Senior Vice President of Quality and Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 18 May 2006
Baxter and Jerini Advance Program to Develop Non-Intravenous Hemophilia Therapy
Biopharmaceuticals

HSMN NewsFeed - 15 May 2006
Dyax Provides Update on Regulatory Pathway for DX-88
Biopharmaceuticals FDA

HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology

Return to NewsFeed

Additional items found! 103

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 103 additional stories matching:
angioedema
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.